p16 immunohistochemistry of multiple primary melanomas as screening to identify Familial Melanoma Syndrome

International Journal of Dermatology

Volumn 51, Issue 4, 2012, Pages 488-492

  Ponti, Giovanni ^a   Luppi, Gabriele ^a   Losi, Lorena ^a   Cesinaro, Anna Maria ^a   Sartori, Giuliana ^a   Maiorana, Antonio ^a   Pellacani, Giovanni ^a   Longo, Caterina ^a   Boni, Elisa ^a   Pepe, Patrizia ^a   Giannetti, Alberto ^a   Seidenari, Stefania ^a   Landi, Maria Teresa ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P16; PROTEIN P53; UVOMORULIN;

ADULT; AGED; CANCER SCREENING; CLINICAL ARTICLE; FAMILIAL CANCER; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; MALE; MELANOMA; MULTIPLE CANCER; PRIMARY TUMOR; PROTEIN EXPRESSION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; BETA CATENIN; CADHERINS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENETIC TESTING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; MUTATION, MISSENSE; MUTS HOMOLOG 2 PROTEIN; NEOPLASMS, MULTIPLE PRIMARY; NUCLEAR PROTEINS; PEDIGREE; SEQUENCE DELETION; SKIN NEOPLASMS; SYNDROME; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84858795694     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2010.04496.x     Document Type: Letter

References (12)

1. Bhatia S, Estrada-Batres L, Maryon T, et al. Second primary tumors in patients with malignant melanoma. Cancer 1999; 86: 2014-2020.
2. Lynch HT, Fusaro RM, Pester J, et al. Familial atypical multiple mole melanoma (FAMMM) syndrome: genetic heterogeneity and malignant melanoma. Br J Cancer 1980; 42: 58-70.
3. Borg A, Sandberg T, Nilsson K, et al. High frequency of multiple melanomas and breast and pancreatic carcinomas in CDKN2A mutation positive melanoma families. J Natl Cancer Inst 2000; 92: 1260-1266.
4. Helsing P, Nymonen DA, Ariansen S, et al. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanoma. Genes Chromosomes Cancer 2008; 47: 175-184.
5. Hashemi J, Platz A, Ueno T, et al. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas. Cancer Res 2000; 60: 6864-6867.
6. Geradts J, Kratzke RA, Niehans GA, et al. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1(CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res 1995; 55: 6006-6011.
7. Sparrow LE, Eldon MJ, English DR, et al. p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry. Am J Dermatopathol 1998; 20: 255-261.
8. Landi MT, Goldstein AM, Tsang S, et al. Genetic susceptibility in familial melanoma from northeastern Italy. J Med Genet 2004; 41: 557-566.
9. de Vries E, Bray FI, Eggermont AM, et al. European Network of Cancer Registries. Monitoring stage-specific trends in melanoma incidence across Europe reveals the need for more complete information on diagnostic characteristics. Eur J Cancer Prev 2004; 13: 387-395.
10. Alonso SR, Ortiz P, Pollán M, et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles. A tissue microarray-based study. Am J Pathol 2004; 164: 193-203.
11. Evangelou K, Bramis J, Peros I, et al. Electron microscopy evidence that cytoplasmic localization of the p16INK4a "nuclear" cyclin-dependent kinase inhibitor (CKI) in tumor cells is specific and not an artifact. A study in non-small cell lung carcinomas. Biotech Histochem 2004; 79: 5-10.
12. Ghiorzo P, Villaggio B, Sementa AR, et al. Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patients. Hum Pathol 2004; 35: 25-33.